JUAN JOSÉ LAHUERTA PALACIOS-rekin lankidetzan egindako argitalpenak (8)

2022

  1. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Cancers, Vol. 14, Núm. 20

2018

  1. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing

    Haematologica

2017

  1. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

    Leukemia

2014

  1. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

    Blood, Vol. 123, Núm. 20, pp. 3073-3079

2013

  1. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma: Results from a GEM/PETHEMA study

    British Journal of Haematology, Vol. 163, Núm. 5, pp. 581-589

2008

  1. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: The prognostic impact of achieving molecular response

    British Journal of Haematology, Vol. 142, Núm. 5, pp. 766-774

2006

  1. Application of self-quenched JH consensus primers for real-time quantitative of PCR of IGH gene to minimal residual disease evaluation in multiple myeloma

    Journal of Molecular Diagnostics, Vol. 8, Núm. 3, pp. 364-370

2004

  1. The use of fluorescent molecular beacons in real time PCR of IgH gene rearrangements for quantitative evaluation of multiple myeloma

    Clinical and Laboratory Haematology, Vol. 26, Núm. 1, pp. 31-35